Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
35M
-
Shares change
-
+748K
-
Total reported value, excl. options
-
$572M
-
Value change
-
+$5.77M
-
Number of buys
-
30
-
Number of sells
-
-21
-
Price
-
$16.32
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q4 2021
63 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q4 2021.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35M shares
of 128M outstanding shares and own 27.39% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.61M shares), HHLR ADVISORS, LTD. (8.76M shares), Miura Global Management, LLC (3.02M shares), FIL Ltd (2.67M shares), FMR LLC (2.67M shares), BlackRock Inc. (2.37M shares), ORBIMED ADVISORS LLC (1.92M shares), VANGUARD GROUP INC (1.21M shares), PURA VIDA INVESTMENTS, LLC (422K shares), and Octagon Capital Advisors LP (400K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.